Published in final edited form as:

Biochemistry. 2006 May 23; 45(20): 6488–6494. doi:10.1021/bi060381e.

DOMINANT NEGATIVE MUTANTS OF TRANSDUCIN- α THAT BLOCK ACTIVATED RECEPTOR[†]

Michael Natochin, Brandy Barren, and Nikolai O. Artemyev*

From the Department of Physiology and Biophysics, University of Iowa College of Medicine, Iowa City, IA 52242

Abstract

Mutations counterpart to dominant negative RasSer17Asn in the α -subunits of heterotrimeric G-proteins are known to also produce dominant negative effects. The mechanism of these mutations remains poorly understood. Here, we examined the effects and mechanism of the Ser43Cys and Ser43Asn mutants of transducin-like chimeric G α^* in the visual signaling system. Our analysis showed that both mutants have reduced affinity for GDP and are likely to exist in an empty- or partially occupied-pocket state. S43C and S43N retained the ability to interact with G $\beta\gamma$ and, as heterotrimeric proteins, bind to photoexcited rhodopsin (R*). The interaction with R* is unproductive as the mutants failed to bind GTP γ S and become activated. S43C and S43N inhibited R*-dependent activation of G α^* and G α , apparently by blocking R*. Finally, both G α^* mutants lacked interaction with the γ -subunit of PDE6, an effector protein in phototransduction. These results indicate that the S43C and S43N mutants of G α^* are dominant negative inhibitors that bind and block the activated receptor in a mechanism that parallels that of RasSer17Asn. Dominant negative mutants of G α sequestering R*, such as S43C and S43N, may become useful instruments in probing the mechanisms of visual dysfunctions caused by abnormal phototransduction signaling.

GTP-binding proteins transduce a vast number of signals inside a cell or across the cell membrane. Small monomeric and larger heterotrimeric proteins represent two distinct families in the superfamily of GTP-binding proteins. At the center of signaling by the two families is a conserved GTPase cycle that switches GTP-binding proteins between two principal states: inactive, GDP-bound, or activated, GTP-bound. A GTP-binding protein is activated by a guanine nucleotide exchange factor (GEF), which induces the release of bound GDP and its exchange for GTP. Intrinsic GTPase activity, often under the control of GTPase-activating proteins (GAPs), inactivates GTP-binding proteins. For heterotrimeric GTP-binding proteins (G-proteins), the function of GEFs is accomplished by agonist-activated G protein-coupled receptors (GPCRs), which induce GDP-release from G α -subunits of cognate G-proteins, followed by binding of GTP and dissociation of G α GTP and G $\beta\gamma$ from the receptor (reviewed in ¹⁻⁷). Dominant negative mutants, particularly those of monomeric GTPases, have been very instrumental in delineating the complexity of signaling pathways by GTP-binding proteins. One of the best characterized dominant negative mutants is RasS17N (^{6, 8}). The serine residue, S17, binds magnesium ion in the nucleotide-binding pocket of GDP- or GTP-bound Ras (^{4, 6}). The S17N mutation reduces Ras's affinity for both GDP and GTP and blocks its ability to reach an active conformation (^{6, 9}). While RasS17N fails to activate effector proteins, its

[†]This work was supported by National Institutes of Health Grant EY12682.

*Correspondence: Nikolai O. Artemyev, Department of Physiology and Biophysics, University of Iowa College of Medicine, 5-532 Bowen Science Building, 51 Newton Rd., Iowa City, IA 52242 Tel. 319/335-7864; FAX 319/335-7330; E-mail: nikolai-artemyev@uiowa.edu

nucleotide-free form binds tightly and sequesters Ras-GEFs, thereby inhibiting signaling by the wild-type Ras (6).

Mutations of the S17 counterpart residue in G α subunits have been also shown to produce the dominant negative phenotype, but the mechanism of these mutants remains poorly understood (10-13). The Cys substitutions of Ser47 in G α or Ser48 in G α_2 yield dominant-negative mutants that seem to exert their effects through sequestration of G $\beta\gamma$ (10, 11). A heterotrimer of G α and G $\beta\gamma$ is a prerequisite for G-protein activation by a GPCR (3). Depletion of G $\beta\gamma$ by G α mutants inhibits the activation of wild-type G-proteins and blocks G $\beta\gamma$ -mediated pathways (14). However, the mechanism of dominant negative G α mutants by G $\beta\gamma$ -sequestration is nonselective and allows for the lingering presence of unblocked activated receptors. In contrast, the mechanism of the dominant negative S54N mutant of G α appears to be similar to that of RasS17N (12, 13). The G α S54N mutant blocked the G α - and G α -mediated signaling from TSH receptor but not the G α -mediated signaling from the α_{1B} -adrenergic receptor, suggesting that G α S54N blocks the TSH receptor (13). These findings indicate that the precise mechanism of the Ser mutants of G α subunits may depend on the type of G α or perhaps the nature of the substitution. Here, we examined the mechanism of the Ser mutations, S43C and S43N, introduced into the transducin-like chimeric protein G α^* ¹, which is readily expressed in *E. coli* (15). Transducin, a member of the Gi/Go family, mediates a classical phototransduction cascade in rod photoreceptor cells. The cascade is initiated by the interaction of photoexcited rhodopsin (R*) with transducin (Gt). G α GTP is subsequently released to activate the effector enzyme PDE6 by displacing the inhibitory P γ subunits from the catalytic core PDE6 $\alpha\beta$. Hydrolysis of cGMP by activated PDE6 results in the closing of cGMP-gated channels in the photoreceptor plasma membrane (16). The ease of purification of rhodopsin in large quantities and the specificity of R*/transducin coupling makes this system an excellent model to probe the mechanism of dominant negative G α mutants. Furthermore, identification and characterization of dominant negative inhibitors of phototransduction may have important implications for potential therapies of specific forms of retinal degeneration caused by excessive visual signaling (17-19).

Experimental procedures

Materials

Guanosine 5'-[γ -³⁵S]thiotriphosphate triethylammonium salt (GTP γ S; 1100 Ci/mmol), nicotinamide adenine [adenylate-³²P]dinucleotide (³²P-NAD; ~1000 Ci/mmol) and PD-10

¹Abbreviations:

Gα	rod G protein (transducin) α -subunit
Gα^*	effector-competent chimeric G α
PDE6	rod outer segment cGMP phosphodiesterase
Pγ	inhibitory subunit of PDE6, ROS (OS), rod outer segment(s)
R*	light-activated rhodopsin
E-ROS	EDTA-stripped ROS membranes
GTPγS	guanosine 5'-O-(3-thiotriphosphate)

Desalting Columns were from Amersham Biosciences. GTP, GDP, and pertussis toxin were from Sigma-Aldrich. *Dpn I* restriction enzyme was from New England Biolabs, Inc. Turbo *Pfu* DNA polymerase was from Stratagene. DH5 α and BL21(DE3) bacterial strains were from Invitrogen. His-Bind resin was from Novagen. Trypsin treated with L-(tosylamido-2-phenyl)-ethylchloromethylketone was from Worthington Biochemical Corp. Primers were synthesized by IDT, Inc. Bovine rod outer segment (ROS) membranes were prepared as described (20). EDTA-washed ROS (E-ROS) were prepared as described (21). Gt $\beta\gamma$ was purified as described (22).

Mutagenesis and expression of Gt α^* S43C and Gt α^* S43N

The Gt α^* S43C and Gt α^* S43N mutants were obtained using the pHis6-Gt α^* vector for expression of the transducin-like chimera, Gt α^* (15), as a template in the PCR amplifications. Reverse Gt α^* primer TCTGCTTGACAATGGTACACTTCCCGGATTCACCG and forward Gt α^* primer CGGTGAATCCGGGAAGTGTACCATTGTCAAGCAGA were used to obtain the mutation S43C (bold) by following the protocol of QuikChange II Site-Directed Mutagenesis Kit (Stratagene). Similarly, the reverse primer Gt α^* TCTGCTTGACAATGGTATTCTTCCCGGATTCACCG and forward Gt α^* primer CGGTGAATCCGGGAAGAATACCATTGTCAAGCAGA were used to obtain the mutation S43N (bold). The constructs were sequenced at the University of Iowa DNA Core Facility. Gt α^* , Gt α^* S43C, and Gt α^* S43N were expressed and purified as described (23).

Trypsin-protection assay

Gt α^* , Gt α^* S43C, and Gt α^* S43N (2 μ g) were incubated in 20 mM HEPES buffer (pH 8.0) containing 100 mM NaCl and 2 mM MgSO $_4$ (buffer A) and 50 μ M GDP for 10 minutes at 25 $^{\circ}$ C. Where indicated, 10 mM NaF and 50 μ M AlCl $_3$ were included in buffer A. For the GTP γ S-bound Gt α^* , Gt α^* S43C, and Gt α^* S43N, 2 μ g of each protein were preincubated with bleached E-ROS (20 nM rhodopsin) and Gt $\beta\gamma$ (0.2 μ g) in the presence of 50 μ M GTP γ S for 1 hour at 25 $^{\circ}$ C. Where indicated, trypsin (10 μ g/ml) was added and the digestion was carried out for 10 minutes at 25 $^{\circ}$ C. Digestions were stopped by heat treatment (100 $^{\circ}$ C) and the addition of SDS-PAGE sample buffer. Proteolytic fragments were analyzed by SDS-gel electrophoresis followed by Coomassie Blue staining.

Analysis of the nucleotide-bound state

Purified Gt α^* , Gt α^* S43C and Gt α^* S43N (400 μ g) were passed through desalting PD-10 columns equilibrated with 20 mM Tris-HCl buffer (pH 8.0) containing 2 mM MgSO $_4$, and the proteins were denatured by boiling for 10 minutes. The samples were centrifuged at 13,000 $\times$ g for 10 minutes and then applied to YM-10 Microcon filters (Millipore). The guanine nucleotide composition of the filtrates was determined by chromatography on a MonoQ anion exchange column (Pharmacia) using a HPLC system (BioRad Model 2800). The column was equilibrated with 20 mM Tris-HCl buffer (pH 8.0) containing 5 mM MgSO $_4$ and 2 mM β -mercaptoethanol. Nucleotides eluted with a linear gradient of NaCl (0-800 mM/16 min) at the flow rate of 0.5 ml/min were monitored at 254 nm. Under these conditions, the elution times of the control GDP and GTP samples were 11.6 and 12.3 min, respectively.

Pertussis toxin-catalyzed ADP-ribosylation

Gt α^* , Gt α^* S43C, and Gt α^* S43N (0.5 μ M) were mixed with Gt $\beta\gamma$ (0-3 μ M) in Buffer A. The reactions were initiated by the addition of 5 μ M [32 P]NAD (0.3 μ Ci) and 3 μ g/ml pertussis toxin (preactivated with 100 mM dithiothreitol and 0.25% SDS for 10 min at 30 $^{\circ}$ C) and allowed to proceed for 1 hour at 25 $^{\circ}$ C. Aliquots from reaction mixtures were filtered through Whatman cellulose nitrate filters. The filters were washed three times with 20 mM Tris-HCl (pH 8.0) buffer containing 130 mM NaCl and 10 mM MgSO $_4$ and counted in a liquid scintillation

counter. Additional aliquots from reaction mixtures were mixed with sample buffer for SDS-PAGE, heat-treated for 5 min at 100 °C, and analyzed by electrophoresis in 12 % gels and autoradiography.

GTP γ S binding assay

Gt α^* , Gt α^* S43C and Gt α^* S43N (1 μ M) mixed with 2 μ M Gt $\beta\gamma$ and E-ROS membranes (0.12 or 0.5 μ M rhodopsin) were incubated for 2 min at 25°C under room light conditions. Binding reactions were initiated with the addition of 20 μ M [35 S]GTP γ S (1 μ Ci). Aliquots of 20 μ l were withdrawn at the indicated times, mixed with 1 ml of ice-cold 20 mM Tris-HCl (pH 8.0) buffer containing 130 mM NaCl, 2 mM MgSO₄, and 1 mM GTP, passed through Whatman cellulose nitrate filters (0.45 μ m), and washed three times with 3 ml of the same buffer without GTP. The filters were dissolved in 5 ml of a xylene-based 3a70B counting cocktail (RPI Corp.) and [35 S]GTP γ S was measured in a liquid scintillation counter. The initial rates for the binding reactions were calculated as the slopes of the linear fits.

To study the effects of the mutants on GTP γ S binding to Gt α^* and Gt α , indicated amounts of the mutants were preincubated with an equimolar concentration of Gt $\beta\gamma$ and indicated concentrations of E-ROS for 3 min at 25°C, followed by the addition of Gt α^* Gt $\beta\gamma$ or holotransducin, Gt (0.3 μ M), and 20 μ M [35 S]GTP γ S (1 μ Ci). Time-courses of GTP γ S binding were determined at 25°C (aliquots withdrawn at 1, 2, and 3 min) and the initial rates of the reactions were calculated and compared.

ROS pull-down assay

E-ROS membranes were resuspended in 50 mM Tris-HCl (pH 7.4) buffer containing 100 mM NaCl and 5 mM MgSO₄. The rhodopsin concentration was calculated using the extinction coefficient 40,600 M⁻¹ cm⁻¹ at A₅₀₀ (24). Gt α^* , Gt α^* S43C and Gt α^* S43N (2 μ M) were mixed with E-ROS (0.5 μ M rhodopsin) in the absence or presence of Gt $\beta\gamma$ (2 μ M) and incubated for 20 minutes at 25°C under room light conditions in 50 mM Tris-HCl (pH 7.4) buffer containing 100 mM NaCl and 5 mM MgSO₄. The samples were centrifuged at 15,000 $\times$ g for 15 minutes at 4°C. Pellets were resuspended in the same buffer and centrifuged three more times. The pellets were resuspended in 20 mM Tris-HCl (pH 7.4) buffer containing 5 mM MgSO₄ and one-half of the membrane suspension (20 μ l) was added to SDS sample buffer followed by heat treatment (100°C, 5 min). The other half was incubated for 30 min at 25°C in a volume of 300 μ l of the same buffer containing 3 mM GTP γ S. The samples were centrifuged at 15,000 $\times$ g for 15 minutes at 4°C. The supernatants were collected, concentrated using Speed Vac (Savant) and SDS sample buffer was added to the concentrated supernatants, followed by heat treatment (100°C, 5 min). The pellets were resuspended in the GTP γ S-containing buffer, incubated for 30 min at 25°C and centrifuged at 15,000 $\times$ g for 15 minutes at 4°C. This step was repeated twice. Finally, SDS sample buffer was added to the pellets followed by heat treatment (100°C, 5 min). Samples were analyzed by SDS-gel electrophoresis followed by Coomassie Blue staining.

“Extra” Metarhodopsin II assay

The absorbance spectra of E-ROS (4 μ M rhodopsin) were measured at 4°C in the absence and presence of 2 μ M transducin or 5 μ M Gt α^* , Gt α^* S43C and Gt α^* S43N prebound with equimolar concentrations of Gt $\beta\gamma$. The assay buffer contained 10 mM MOPS (pH 7.6), 2 mM MgSO₄, 1 mM dithiothreitol, 200 mM NaCl, and, where indicated, 100 μ M GTP γ S. A dark spectrum was recorded first. A second spectrum was measured 1 min after 10-sec of bleaching with a 150 W light source at a distance of 10 cm. The difference between the two spectra was calculated. Metarhodopsin II was assessed as the difference between the absorbance at 380 nm and 420 nm (21, 25).

Py fluorescence-binding assay

Fluorescence-binding measurements were performed on a F-2500 Fluorescence Spectrophotometer (Hitachi) in 0.5 ml of buffer A at 25°C. Fluorescence of Py labeled with 3-(bromoacetyl)-7-diethylaminocoumarin (PyBC, 15 nM) (26) was measured with an excitation of 445 nm and emission of 495 nm in the presence of increasing concentrations of the GDP-, AlF_4^- , or GTP γ S-bound $\text{G}\alpha^*$, $\text{G}\alpha^*\text{S43C}$, or $\text{G}\alpha^*\text{S43N}$. The AlF_4^- - and GTP γ S-bound proteins were obtained by preincubation of 10 mM NaF and 50 μM AlCl_3 for 10 min, or 50 μM GTP γ S in the presence of bleached uROS membranes (100 nM rhodopsin) and Gt $\beta\gamma$ (100 nM) for 1 hour, followed by centrifugation for 15 minutes at $13,000 \times g$.

Miscellaneous procedures

Protein concentrations were measured using IgG as a standard as described (27). SDS-PAGE was performed using 12% acrylamide gels. GraphPad Prism (version 4) was used to fit the experimental data and plot the graphs. Results are expressed as mean $\pm$ S.E. for three independent experiments.

Results

Expression and trypsin sensitivity of the $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$ mutants

Two mutations, S43C and S43N, were introduced into the $\text{G}\alpha$ -like chimeric protein $\text{G}\alpha^*$, which is readily expressed in *E. coli* (15). This effector competent $\text{G}\alpha^*$ was generated previously, based on the $\text{G}\alpha/\text{G}\alpha$ Chi8 (23), by introducing two $\text{G}\alpha$ -specific residues H244 and N247 (15). The yields of purified $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$ mutants were similar (~ 1 mg/L of culture). A trypsin protection assay was performed to assess the folding and nucleotide-binding state of the mutants. When $\text{G}\alpha^*$ becomes activated (GDP- AlF_4^- - or GTP γ S-bound), a conformational change occurs which protects the switch II region from tryptic cleavage and results in the appearance of a ~ 34 kDa band. As expected, the trypsin-protection test of $\text{G}\alpha^*$ showed a ~ 20 kDa band in the GDP-bound state, and a ~ 34 band for the AlF_4^- - and GTP γ S-activated conformations (Fig. 1). In contrast, the $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$ mutants were fully proteolyzed by trypsin regardless of the presence of GDP, GDP- AlF_4^- or GTP γ S (Fig. 1). The absence of the ~ 20 and ~ 34 kDa bands indicates that the mutants are either deficient in GDP and GTP binding, or their guanine nucleotide-bound conformations are different from those of $\text{G}\alpha^*$.

Nucleotide bound state of $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$

To further elucidate the nucleotide-bound state of $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$, the mutants were denaturated to release bound nucleotide, which was identified by HPLC. The HPLC profiles show that the $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$ mutants contain a negligible amount of bound GDP compared to $\text{G}\alpha^*$ when the same amount of proteins was analyzed (Fig. 2). This correlates with the results of the trypsin-protection test and shows that the mutants have a severely reduced affinity for GDP and are likely to exist in an empty-pocket state.

Gt $\beta\gamma$ -dependent pertussis toxin-catalyzed ADP-ribosylation of $\text{G}\alpha^*$, $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$

We next examined the ability of the mutants to interact with Gt $\beta\gamma$. $\text{G}\alpha^*\text{GDP}$ is known to be ADP-ribosylated by pertussis toxin at Cys347 (28, 29). Since holotransducin Gt $\alpha\beta\gamma$ is a notably better substrate than the $\text{G}\alpha$ -subunit alone (30), ADP-ribosylation by pertussis toxin is a sensitive assay to assess the interaction between $\text{G}\alpha$ and Gt $\beta\gamma$. $\text{G}\alpha^*$, $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$ all showed increased ADP-ribosylation in a Gt $\beta\gamma$ dose-dependent manner (Fig. 3). Although the $\text{G}\alpha^*\text{S43C}$ and $\text{G}\alpha^*\text{S43N}$ mutants required slightly higher concentrations of

Gt $\beta\gamma$ to produce equivalent effects compared to Gt α^* , they are clearly capable of interacting with Gt $\beta\gamma$.

Gt α^* S43C and Gt α^* S43N are not activated by R*

The ability of Gt α^* S43C and Gt α^* S43N to interact with Gt $\beta\gamma$ allowed us to test the functional coupling of the heterotrimeric mutants to R*. Control experiments demonstrated the R*-dependent kinetics of GTP γ S-binding to Gt α^* in the presence of Gt $\beta\gamma$ (Fig. 4). Unlike Gt α^* , both Gt α^* S43C and Gt α^* S43N did not appreciably bind GTP γ S even when using a relatively high concentration of R* (Fig. 4). This result suggests that the mutants either fail to interact with R*, or they bind to R*, but fail to subsequently bind GTP γ S and assume an activated conformation.

Binding of Gt α^* , Gt α^* S43C and Gt α^* S43N to R*

To determine if Gt α^* S43C and Gt α^* S43N retained the ability to bind to R*, direct mutant binding to E-ROS was investigated in the presence or absence of Gt $\beta\gamma$ (Fig. 5). Both mutants bound to E-ROS membranes in the presence, but not in the absence of Gt $\beta\gamma$. Moreover, the mutant binding was comparable to the binding of Gt α^* . The addition of GTP γ S to the E-ROS membranes caused activation and elution of Gt α^* , but not Gt α^* S43C, supporting the mutant's inability to bind guanine nucleotides (Fig. 5). The GTP γ S-induced elution of Gt α^* S43N was markedly reduced with most of the mutant remaining membrane-bound (Fig. 5).

To prove that the binding of Gt α^* S43C and Gt α^* S43N to E-ROS membranes reflects their interaction with R*, we performed the MII-stabilization assay (25). Through a chain of intermediate photoproducts, photoexcitation of rhodopsin leads to an equilibrium between metarhodopsin I and metarhodopsin II (MII) (31), of which MII (R*) is the photoproduct that binds and activates Gt (32). When ROS membranes are bleached in the presence of Gt, the stable interaction between MII and Gt in the absence of GTP leads to the formation of extra MII (25). The spectroscopic measurements of MII showed that both Gt α^* S43C and Gt α^* S43N stabilize MII similar to native Gt α and Gt α^* (Fig. 6). As expected, the addition of GTP γ S reversed the MII stabilization effects of Gt α and Gt α^* . In contrast, GTP γ S had little or no effect on the MII formation in the presence of Gt α^* S43C and Gt α^* S43N (Fig. 6).

Gt α^* S43C and Gt α^* S43N inhibit R*-stimulated GTP γ S-binding to Gt α^* and Gt α

Intact binding of Gt α^* S43C and Gt α^* S43N to R* coupled with their inability to bind GTP γ S and be released from the complex with receptor indicated that the mutants may compete with Gt α^* for R* and block Gt α^* activation. To test this hypothesis, we examined GTP γ S binding to Gt α^* in the presence of increasing concentrations of the mutants. Gt α^* and the mutants were reconstituted with equimolar amounts of Gt $\beta\gamma$ to exclude effects due to Gt $\beta\gamma$ sequestration. As shown on Figure 7A, the initial rates of GTP γ S binding to Gt α^* decreased in a Gt α^* S43C and Gt α^* S43N dose-dependent manner. Gt α^* S43N appeared to be a somewhat more potent inhibitor compared to Gt α^* S43C. The addition of a 10-fold excess of Gt α^* S43N over Gt α^* reduced the GTP γ S binding rate by ~90% (Fig. 7A). We also examined the ability of Gt α^* S43C and Gt α^* S43N to block the R*-dependent activation of native Gt isolated from bovine ROS. In this experiment, a lower concentration of E-ROS (30 nM rhodopsin) was used to achieve an initial GTP γ S-binding rate similar to that for Gt α^* Gt $\beta\gamma$ using 150 nM rhodopsin. The mutants also markedly inhibited GTP γ S-binding to Gt (Fig. 7B).

Gt α^* S43C and Gt α^* S43N fail to interact with the γ -subunit of PDE6

GDP-bound Gt α is known to have a basal affinity for the PDE6 γ -subunit, which is markedly enhanced in the AlF $_4^-$ or GTP γ S-activated conformations of Gt α (26, 33). This increase in the interaction with P γ can be monitored by a binding assay utilizing fluorescently labeled P γ ,

PyBC (26). The fluorescence binding assay was performed to determine whether the conformations of G α *S43C and G α *S43N allow them to bind Py. No interaction of either mutant with PyBC was detected, regardless the presence of GDP, GDP-AlF $_4^-$ (Fig. 8) or GTP γ S (not shown). In control experiments, G α * displayed an ~8 fold and a ~14 fold increase in the affinity for PyBC when activated by AlF $_4^-$ (Fig 8) and GTP γ S, respectively (not shown).

Discussion

A number of mutant G α subunits exerting often only weak dominant negative effects have been described (34-37). Activation of heterotrimeric G-proteins by agonist-bound GPCRs releases potentially two signaling species: G α GTP and G $\beta\gamma$. Consequently, dominant negative mutants of G α might act by blocking GPCRs, by inhibiting G α GTP-mediated activation of effectors or by sequestering G $\beta\gamma$. To date, no dominant negative mutant G α subunits that effectively prevent activation of effectors by G α GTP have been identified. Two mutations of G α , G225T and G226A, were shown to reduce its ability to bind GTP and assume an activated conformation (34, 35). These G α mutants were reported to inhibit hormone-induced stimulation of adenylyl cyclase. Corresponding mutations in G α_2 also produced dominant negative effects (36, 37). The main mechanism of the G α mutants with the impaired ability to undergo activation conformational change is likely based on the sequestration of G $\beta\gamma$ (14). G α mutants sequestering only G $\beta\gamma$ would be potent inhibitors of G-protein signaling mediated by G $\beta\gamma$. However, such mutants would not be efficient in blocking G-protein pathways with G α GTP as transducers due to the catalytic role of G $\beta\gamma$ during G-protein activation by GPCRs (14). Concentrations of G $\beta\gamma$ much lower than stoichiometric may allow significant activation of G α . Therefore, the most effective and specific mechanism for a dominant negative G α should involve the sequestration of activated GPCRs, just as RasS17N binds and blocks Ras-GEFs. A stable empty-pocket complex between G $\alpha\beta\gamma$ and GPCR is formed in the absence of guanine nucleotides (3, 5). With this rationale, a triple dominant negative mutant that combined mutations reducing G α 's affinity for both GDP and GTP was designed (14). This mutant was shown to be a robust and selective inhibitor of Gs-dependent hormonal stimulation of adenylyl cyclase, presumably through the sequestration of activated GPCR (14). Still, mutants in G α subunits with a substitution at the position corresponding to RasS17 remain the best candidates as singly-mutated dominant negative inhibitors. The mechanism of these mutants remains controversial (10-13). G α S54N was shown to block the TSH receptor (13), whereas G α S47C and G α_2 S48C were reported to act through sequestration of G $\beta\gamma$ (10, 11).

We have generated the S43C and S43N mutants of transducin-like G α * and examined their effects on the rhodopsin/transducin/PDE6 visual signaling pathway. Our results demonstrate that both mutants have reduced affinity for guanine nucleotides and are likely to exist in an empty- or partially occupied-pocket state. G α *S43C and G α *S43N retained the ability to interact with G $\beta\gamma$ and, as heterotrimeric proteins, bind R*. The interaction with R* is unproductive in that the mutants fail to bind GTP γ S and become activated. Moreover, by binding and blocking R*, G α *S43C and G α *S43N can inhibit R*-dependent activation of G α . Finally, G α *S43C and G α *S43N did not show any interaction with the effector protein. Therefore, both mutants are dominant negative inhibitors that bind and block the activated receptor similarly to the effects of G α S54N (13). Yet, unlike the G α * mutants, G α S54N appears to retain some GTP-binding capacity and can increase basal cellular cAMP levels in the absence of hormonal stimulation (12, 13).

Our results suggest that the dominant negative mechanism of the Ser residue mutations in G α subunits is not dependent on the type of G-protein (Gs or Gi/o/t) or on the type of mutation (Asn or Cys). Theoretically, the Ser to Asn or Cys mutants in all G α families should be capable to some extent of blocking activated cognate GPCRs. This study is the second report of a dominant negative transducin- α . A recent study had reported a negative dominant phenotype

for transducin- α mutant R238E (38). However, our subsequent investigation of G α *R238E revealed properties entirely inconsistent with those of a dominant negative inhibitor (39). In contrast to the reported phenotype (38), we found that G α *R238E binds GDP and GTP, and is fully capable of activational coupling to R* (39).

A number of visual disorders, including certain forms of inherited and light-induced retinal degenerations or stationary night blindness, are caused by excessive phototransduction signaling (17–19). Often, the source of excessive signaling is constitutive activity or inadequate inactivation of the visual receptor (17–19). Dominant negative mutants of G α that sequester R* and block activation of native Gt, such as S43C and S43N, may become very useful instruments in probing the mechanisms of visual dysfunctions. They could also potentially serve as therapeutical tools for more severe forms of retinal degeneration due to abnormal phototransduction.

References

1. Gilman AG. G proteins: transducers of receptor-generated signals. *Annu. Rev. Biochem* 1987;56:615–649. [PubMed: 3113327]
2. Lowy DR, Willumsen BM. Function and regulation of ras. *Annu. Rev. Biochem* 1993;62:851–891. [PubMed: 8352603]
3. Bourne HR. How receptors talk to trimeric G proteins. *Curr. Opin. Cell Biol* 1997;9:134–142. [PubMed: 9069253]
4. Geyer M, Wittinghofer A. GEFs, GAPs, GDIs and effectors: taking a closer (3D) look at the regulation of Ras-related GTP-binding proteins. *Curr. Opin. Struct. Biol* 1997;7:786–792. [PubMed: 9434896]
5. Hamm HE. The many faces of G protein signaling. *J. Biol. Chem* 1998;273:669–672. [PubMed: 9422713]
6. Feig LA. Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases. *Nat. Cell. Biol* 1999;1:E25–27. [PubMed: 10559887]
7. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. *Nat. Rev. Mol. Cell. Biol* 2002;3:639–650. [PubMed: 12209124]
8. Powers S, O'Neill K, Wigler M. Dominant yeast and mammalian RAS mutants that interfere with the CDC25-dependent activation of wild-type RAS in *Saccharomyces cerevisiae*. *Mol. Cell. Biol* 1989;9:390–395. [PubMed: 2651897]
9. John J, Rensland H, Schlichting I, Vetter I, Borasio GD, Goody RS, Wittinghofer A. Kinetic and structural analysis of the Mg²⁺-binding site of the guanine nucleotide-binding protein p21H-ras. *J. Biol. Chem* 1993;268:923–929. [PubMed: 8419371]
10. Slepak VZ, Quick MW, Aragay AM, Davidson N, Lester HA, Simon MI. Random mutagenesis of G protein α subunit G(o) α . Mutations altering nucleotide binding. *J. Biol. Chem* 1993;268:21889–21894. [PubMed: 8408043]
11. Slepak VZ, Katz A, Simon MI. Functional analysis of a dominant negative mutant of Gai2. *J. Biol. Chem* 1995;270:4037–4041. [PubMed: 7876152]
12. Cleator JH, Mehta ND, Kurtz DT, Hildebrandt JD. The N54 mutant of G α s has a conditional dominant negative phenotype which suppresses hormone-stimulated but not basal cAMP levels. *FEBS Lett* 1999;443:205–208. [PubMed: 9989606]
13. Cleator JH, Ravenell R, Kurtz DT, Hildebrandt JD. A dominant negative G α s mutant that prevents thyroid-stimulating hormone receptor activation of cAMP production and inositol 1,4,5-trisphosphate turnover: competition by different G proteins for activation by a common receptor. *J. Biol. Chem* 2004;279:36601–36607. [PubMed: 15234971]
14. Iiri T, Bell SM, Baranski TJ, Fujita T, Bourne HR. G α s mutant designed to inhibit receptor signaling through Gs. *Proc. Natl. Acad. Sci. USA* 1999;96:499–504. [PubMed: 9892662]
15. Muradov KG, Artemyev NO. Loss of the effector function in a transducin- α mutant associated with Nougaret night blindness. *J. Biol. Chem* 2000;275:6969–6974. [PubMed: 10702259]
16. Arshavsky VY, Lamb TD, Pugh EN Jr. G proteins and phototransduction. *Annu. Rev. Physiol* 2002;64:153–187. [PubMed: 11826267]

17. Dryja TP. Molecular genetics of Oguchi disease, fundus albipunctatus, and other forms of stationary night blindness: LVII Edward Jackson Memorial Lecture. *Am. J. Ophthalmol* 2000;130:547–563. [PubMed: 11078833]
18. Pierce EA. Pathways to photoreceptor cell death in inherited retinal degenerations. *Bioessays* 2001;23:605–618. [PubMed: 11462214]
19. Lem J, Fain GL. Constitutive opsin signaling: night blindness or retinal degeneration? *Trends Mol. Med* 2004;10:150–157. [PubMed: 15059605]
20. Papermaster DS, Dreyer WJ. Rhodopsin content in the outer segment membranes of bovine and frog retinal rods. *Biochemistry* 1974;13:2438–2444. [PubMed: 4545509]
21. Dratz EA, Furstenu JE, Lambert CG, Thireault DL, Rarick H, Schepers T, Pakhlevanians S, Hamm HE. NMR structure of a receptor-bound G-protein peptide. *Nature* 1993;363:276–281. [PubMed: 8487866]
22. Kleuss C, Pallast M, Brendel S, Rosenthal W, Schultz G. Resolution of transducin subunits by chromatography on blue sepharose. *J. Chromatogr* 1987;407:281–289. [PubMed: 3480892]
23. Skiba NP, Bae H, Hamm HE. Mapping the effector binding sites of transducin α -subunit using *Gat/Gai1* chimeras. *J. Biol. Chem* 1996;271:413–424. [PubMed: 8550597]
24. Wald G, Brown PK. The molar extinction of rhodopsin. *J. Gen. Physiol* 1953;37:189–200. [PubMed: 13109155]
25. Emeis D, Kuhn H, Reichert J, Hofmann KP. Complex formation between metarhodopsin II and GTP-binding protein in bovine photoreceptor membranes leads to a shift of the photoproduct equilibrium. *FEBS Lett* 1982;143:29–34. [PubMed: 6288450]
26. Artemyev NO. Binding of transducin to light-activated rhodopsin prevents transducin interaction with the rod cGMP phosphodiesterase γ -subunit. *Biochemistry* 1997;36:4188–493. [PubMed: 9100013]
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of proteins utilizing the principle of protein-dye binding. *Anal. Biochem* 1976;72:248–254. [PubMed: 942051]
28. van Dop C, Yamanaka G, Steinberg F, Sekura RD, Manclark CR, Stryer L, Bourne HR. ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors. *J. Biol. Chem* 1984;259:23–26. [PubMed: 6142883]
29. West RE Jr, Moss J, Vaughan M, Liu T, Liu TY. Pertussis toxin-catalyzed ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site. *J. Biol. Chem* 1985;260:14428–14430. [PubMed: 3863818]
30. Watkins PA, Burns DL, Kanaho Y, Liu TY, Hewlett EL, Moss J. ADP-ribosylation of transducin by pertussis toxin. *J. Biol. Chem* 1985;260:13478–13482. [PubMed: 3863817]
31. Wald G. The molecular basis of visual excitation. *Nature* 1968;219:800–807. [PubMed: 4876934]
32. Bennett N, Michel-Villaz M, Kuhn H. Light-induced interaction between rhodopsin and the GTP-binding protein. Metarhodopsin II is the major photoproduct involved. *Eur. J. Biochem* 1982;127:97–103. [PubMed: 6291939]
33. Otto-Bruc A, Antonny B, Vuong TM, Chardin P, Chabre M. Interaction between the retinal cyclic GMP phosphodiesterase inhibitor and transducin. Kinetics and affinity studies. *Biochemistry* 1993;32:8636–8645. [PubMed: 8395212]
34. Miller RT, Masters SB, Sullivan KA, Beiderman B, Bourne HR. A mutation that prevents GTP-dependent activation of the α chain of Gs. *Nature* 1988;334:712–715. [PubMed: 3137475]
35. Osawa S, Johnson GL. A dominant negative G α s mutant is rescued by secondary mutation of the α chain amino terminus. *J. Biol. Chem* 1991;266:4673–4676. [PubMed: 1848223]
36. Hermouet S, Merendino JJ Jr, Gutkind JS, Spiegel AM. Activating and inactivating mutations of the alpha subunit of Gi2 protein have opposite effects on proliferation of NIH 3T3 cells. *Proc. Natl. Acad. Sci. USA* 1991;88:10455–10459. [PubMed: 1660138]
37. Murray-Whelan R, Reid JD, Piuz I, Hezareh M, Schlegel W. The guanine-nucleotide-binding protein subunit G α i2 is involved in calcium activation of phospholipase A2. Effects of the dominant negative G α i2 mutant, [G203T]G α i2, on activation of phospholipase A2 in Chinese hamster ovary cells. *Eur. J. Biochem* 1995;230:164–169. [PubMed: 7601096]
38. Pereira R, Cerione RA. A switch 3 point mutation in the α subunit of transducin yields a unique dominant-negative inhibitor. *J. Biol. Chem* 2005;280:35696–35703. [PubMed: 16103122]

39. Barren B, Natochin M, Artemyev NO. Mutation R238→E in transducin- α yields a GTPase and effector-deficient, but not dominant-negative G-protein α -subunit. Mol. Vis. 2006;2006:in press

Fig. 1. Trypsin-protection assay of Gtα*, Gtα*S43C and Gtα*S43N

Gtα*, Gtα*S43C and Gtα*S43N (2 μg) were treated with trypsin (10 μg/ml) for 10 min at 25°C in the presence of 50 μM GDP alone, or 50 μM GDP, 10 mM NaF and 50 μM AlCl₃. The GTP_γS-bound proteins were obtained as described under Experimental Procedures. Samples were analyzed by SDS-PAGE in 12% gels and stained with Coomassie Blue.

Fig. 2. Analysis of the nucleotides released from Gtα*, Gtα*S43C and Gtα*S43N
Nucleotides bound to Gtα*, Gtα*S43C and Gtα*S43N (400 μg) were released by boiling for 10 minutes, filtrated through YM-10 Microcon filters, and separated on a MonoQ column as described under Experimental Procedures. The retention times for the GDP and GTP standards were 11.6 and 12.3 min, respectively.

Fig. 3. Gtβγ-dependent ADP-ribosylation of Gtα*, Gtα*S43C and Gtα*S43N
 Pertussis toxin-catalyzed [³²P]ADP-ribosylation of Gtα*, Gtα*S43C and Gtα*S43N (0.5 μM each) was performed in the presence of increasing concentrations of Gtβγ (0, 0.3, 1.0 and 3 μM) as described under Experimental Procedures. Samples were analyzed by SDS-PAGE in 12% gels followed by autoradiography (**A**), or by filtering through Whatman cellulose nitrate filters and counting the filters in a liquid scintillation counter (**B**).

Fig. 4. Kinetics of GTP γ S binding to Gt α^* , Gt α^* S43C and Gt α^* S43N

The binding of GTP γ S to Gt α^* (■, ▲), Gt α^* S43C (▼) and Gt α^* S43N (◆; 1 μ M each) in the presence of 2 μ M Gt $\beta\gamma$ and E-ROS membranes (120 nM rhodopsin ■; 500 nM rhodopsin ▲, ▼, ◆) was initiated by the addition of 20 μ M [35 S]GTP γ S. Aliquots were withdrawn at the indicated time points, passed through Whatman cellulose nitrate filters (0.45 μ m) and counted in a liquid scintillation counter. The k_{app} values (min^{-1}) are: (■) 0.14 ± 0.01 , (▲) 0.56 ± 0.04 .

Fig. 5. Binding of Gtα*, Gtα*S43C and Gtα*S43N to ROS membranes

Gtα*, Gtα*S43C and Gtα*S43N (2 μM each) and EDTA-stripped ROS membranes containing 0.5 μM rhodopsin were incubated in the absence or presence of Gtβγ (2 μM) for 20 minutes at 25°C, centrifuged and washed twice with isotonic buffer. Aliquots of E-ROS were analyzed by SDS-electrophoresis (left two lanes for each construct), while additional aliquots of E-ROS with bound Gtα*βγ or mutants were used for extraction with hypotonic buffer containing 3 mM GTP_γS as described under Experimental Procedures. The membrane pellets (p) and the supernatants (s) after the addition of GTP_γS were analyzed by SDS-electrophoresis (right two lanes for each construct).

Fig. 6. The Meta II stabilization by Gtα*, Gtα*S43C and Gtα*S43N

The absorbance spectra of E-ROS (4 μM rhodopsin) were measured at 4°C in the absence and presence of 2 μM holotransducin (Gt) or 5 μM Gtα*, Gtα*S43C and Gtα*S43N prebound with equimolar Gtβγ. The assay buffer contained 10 mM MOPS (pH 7.6), 2 mM MgSO₄, 1 mM dithiotreitol and 200 mM NaCl (filled bars), and 100 μM GTPγS (open bars). A dark spectrum was recorded first. A second spectrum was measured 1 min after 10-sec of bleaching with a 150 watt light source at a distance of 10 cm. The difference between the two spectra was calculated. Metarhodopsin II was assessed as the difference between the absorbance at 380 nm and 420 nm.

Fig. 7. Gt α^* S43C and Gt α^* S43N inhibit R*-stimulated GTP γ S-binding to Gt α^* and Gt
 Gt α^* S43C and Gt α^* S43N (0.5–3 μ M) were preincubated with an equimolar concentration of Gt $\beta\gamma$ and E-ROS (**A**, 150 nM, **B**, 30 nM rhodopsin) for 3 min at 25°C, followed by the addition of Gt α^* Gt $\beta\gamma$ (**A**) or holotransducin, Gt (**B**) (0.3 μ M each), and 20 μ M [³⁵S]GTP γ S (1 μ Ci). Time-courses of GTP γ S binding were determined at 25°C (aliquots withdrawn at 1, 2, and 3 min) and the initial rates of the reactions were calculated.

Fig. 8. Binding of Gtα*, Gtα*S43C and Gtα*S43N to PyBC

The relative increase in fluorescence (F/F_0) of PyBC (15 nM) (excitation at 445 nm, emission at 495 nm) was determined in the presence of increasing concentrations of Gtα* (■, □) Gtα*S43C (▲, △), and Gtα*S43N (▼, ▽) in the GDP-(closed symbols) or GDP-AlF₄⁻-bound (open symbols) conformations. The K_d values for Gtα* (nM) are: (■) 75 ± 8 and (□) 9 ± 2 .